Statistical Considerations for Evaluating Treatment Effect under Various Non-proportional Hazard Scenarios
Xinyu Zhang, Erich J. Greene, Ondrej Blaha, Wei Wei

TL;DR
This study systematically compares various statistical methods for analyzing time-to-event data under proportional and nonproportional hazard scenarios, using real oncology trial data and simulations to evaluate their performance.
Contribution
It introduces a comprehensive evaluation framework for multiple methods, including novel metrics for bias, and provides tailored recommendations for each hazard scenario.
Findings
MaxCombo and GGM outperform Log-rank in nonproportional hazards
New metrics effectively assess time-dependent bias in treatment effect estimates
Recommendations vary depending on the hazard scenario and method performance
Abstract
We conducted a systematic comparison of statistical methods used for the analysis of time-to-event outcomes under various proportional and nonproportional hazard (NPH) scenarios. Our study used data from recently published oncology trials to compare the Log-rank test, still by far the most widely used option, against some available alternatives, including the MaxCombo test, the Restricted Mean Survival Time Difference (dRMST) test, the Generalized Gamma Model (GGM) and the Generalized F Model (GFM). Power, type I error rate, and time-dependent bias with respect to the RMST difference, survival probability difference, and median survival time were used to evaluate and compare the performance of these methods. In addition to the real data, we simulated three hypothetical scenarios with crossing hazards chosen so that the early and late effects 'cancel out' and used them to evaluate the…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsStatistical Methods in Clinical Trials
